Gene therapy injection aims to ease diabetic eye swelling
NCT ID NCT07362927
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a gene therapy called LX111 for diabetic macular edema (DME), a condition that causes vision loss due to swelling in the retina. About 32 adults with DME will receive a single injection into the eye. The main goals are to check safety and see if it helps improve vision and reduce swelling.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA (DME) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, China
-
Zhongshan Hospital
NOT_YET_RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new eye injection beat the current standard for diabetic vision loss?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug EYE103 takes on lucentis in major trial for Diabetes-Related vision loss
- New dosing strategy could mean fewer eye injections for Diabetes-Related vision loss
- New syringe could simplify High-Dose eye treatment
- Eye scan showdown: faricimab vs ranibizumab in diabetic retinopathy